When caring for a patient with an electrical burn injury, the registered nurse would ask for a health care provider's order for:

Choice A rationale

Cyanosis is a bluish discoloration of the skin and mucous membranes resulting from an increased amount of deoxygenated hemoglobin, typically when it exceeds 5 g/dL. While it is a sign of severe hypoxemia, it is considered a late clinical manifestation rather than an early one. Many patients may be significantly hypoxic before cyanosis ever becomes visible, making it an unreliable indicator for early nervous system or systemic oxygen deprivation.

Choice B rationale

Tachypnea, or an increased respiratory rate, is a compensatory physiological response to hypoxemia mediated by peripheral chemoreceptors in the carotid and aortic bodies. While it occurs early in the progression of respiratory distress, it is a manifestation of the respiratory system's attempt to improve gas exchange and acid-base balance. It does not directly represent the primary, initial impact of falling oxygen levels on the central nervous system's cognitive or behavioral functions.

Choice C rationale

Restlessness is a hallmark early sign of cerebral hypoxia. The brain is highly sensitive to oxygen fluctuations, and a decrease in arterial oxygen tension (PaO2 < 80 mmHg) quickly alters neurotransmitter function and neuronal metabolism. This often manifests as agitation, anxiety, or restlessness before more profound physiological changes like bradycardia or cyanosis occur. Monitoring for these subtle behavioral shifts is critical for the early detection of deteriorating oxygenation status in acute clinical settings.

Choice D rationale

Tachycardia is an early cardiovascular compensatory mechanism where the heart rate increases to boost cardiac output and delivery of available oxygen to tissues. While it often occurs simultaneously with early nervous system changes, it is a circulatory response rather than a direct nervous system sign. A normal adult heart rate is 60 to 100 beats per minute, and elevation above this range during hypoxemia is driven by sympathetic nervous system activation.

Choice A rationale

Rest and watchful waiting are typically management strategies used for acute hepatitis A or sometimes acute hepatitis B, but they are not the standard of care for chronic hepatitis C. Chronic hepatitis C is a progressive viral infection that leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma if left untreated. Because the virus continuously replicates and causes ongoing inflammatory damage to the hepatocytes, a passive approach is scientifically inadequate to prevent long term liver failure and mortality.

Choice B rationale

Immune globulins provide passive immunity and are used for post-exposure prophylaxis in hepatitis A or hepatitis B to prevent the development of an active infection. However, immune globulin has no proven efficacy in treating a well-established chronic hepatitis C infection. The hepatitis C virus has high genetic variability and undergoes rapid mutation, making it an ineffective target for standard immune globulin preparations. Treatment requires direct action against the viral replication cycle rather than a temporary immune boost.

Choice C rationale

Antiviral medications, specifically direct-acting antivirals, are the definitive treatment for chronic hepatitis C. These drugs work by targeting specific nonstructural proteins of the virus, such as NS3/4A, NS5A, or NS5B, which are essential for viral RNA replication and assembly. Modern regimens can achieve a sustained virologic response, which is effectively a cure, in over 95 percent of patients. Clearing the virus stops the progression of liver inflammation and allows the hepatic tissue to begin healing.

Choice D rationale

Fresh-frozen plasma is a blood product used to replace clotting factors in patients with severe coagulopathy or active bleeding, often seen in end-stage liver disease. While a patient with chronic hepatitis C might eventually need fresh-frozen plasma if they develop advanced cirrhosis and liver failure, it is not a treatment for the hepatitis C virus itself. It only manages the symptomatic complications of liver dysfunction rather than addressing the underlying viral etiology responsible for the hepatic damage.